Monica Arena1, Enzo Masci2, Leonardo Henry Eusebi3, Giuseppe Iabichino1, Benedetto Mangiavillano4, Paolo Viaggi1, Elisabetta Morandi1, Lorella Fanti5, Antonino Granata6, Mario Traina6, Pier Alberto Testoni5, Enrico Opocher7, Carmelo Luigiano8. 1. Digestive Endoscopy Unit, San Paolo Hospital, 20142 Milano, Italy. 2. Diagnostic and Therapeutic Endoscopy Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy. 3. Gastroenterology and Endoscopy Unit, Department of Medical and Surgical Sciences, Sant'Orsola University Hospital, Bologna, Italy. 4. Gastroenterology and Digestive Endoscopy Unit, General Hospital of Sanremo, 18038 Sanremo, Italy. 5. Division of Gastroenterology and Gastrointestinal Endoscopy, Vita-Salute San Raffaele University, Scientific Institute San Raffaele, Milan, Italy. 6. Endoscopy Service, Department of Diagnostic and Therapeutic Services, IRCCS-ISMETT, Palermo, Italy. 7. Hepatobiliopancreatic and Digestive Surgery Unit, Department of Surgery, San Paolo Hospital, University of Milan, Italy. 8. Digestive Endoscopy Unit, San Paolo Hospital, 20142 Milano, Italy. Electronic address: carmeluigiano@libero.it.
Abstract
BACKGROUND: Hemospray is a new endoscopic haemostatic powder that can be used in the management of upper gastrointestinal bleedings. AIMS: To assess the efficacy and safety of Hemospray as monotherapy for the treatment of acute upper gastrointestinal bleeding due to cancer. METHODS: The endoscopy databases of 3 Italian Endoscopic Units were reviewed retrospectively and 15 patients (8 males; mean age 74 years) were included in this study. RESULTS: Immediate haemostasis was achieved in 93% of cases. Among the successful cases, 3 re-bled, one case treated with Hemospray and injection had a good outcome, while 2 cases died both re-treated with Hemospray, injection and thermal therapy. No complications related to Hemospray occurred. Finally, 80% of patients had a good clinical outcome at 30days and 50% at six months. CONCLUSION: Hemospray may be considered an effective and safe method for the endoscopic management of acute neoplastic upper gastrointestinal bleedings.
BACKGROUND: Hemospray is a new endoscopic haemostatic powder that can be used in the management of upper gastrointestinal bleedings. AIMS: To assess the efficacy and safety of Hemospray as monotherapy for the treatment of acute upper gastrointestinal bleeding due to cancer. METHODS: The endoscopy databases of 3 Italian Endoscopic Units were reviewed retrospectively and 15 patients (8 males; mean age 74 years) were included in this study. RESULTS: Immediate haemostasis was achieved in 93% of cases. Among the successful cases, 3 re-bled, one case treated with Hemospray and injection had a good outcome, while 2 cases died both re-treated with Hemospray, injection and thermal therapy. No complications related to Hemospray occurred. Finally, 80% of patients had a good clinical outcome at 30days and 50% at six months. CONCLUSION: Hemospray may be considered an effective and safe method for the endoscopic management of acute neoplastic upper gastrointestinal bleedings.
Authors: Mansour A Parsi; Allison R Schulman; Harry R Aslanian; Manoop S Bhutani; Kuman Krishnan; David R Lichtenstein; Joshua Melson; Udayakumar Navaneethan; Rahul Pannala; Amrita Sethi; Guru Trikudanathan; Arvind J Trindade; Rabindra R Watson; John T Maple Journal: VideoGIE Date: 2019-06-27
Authors: Muhammad Aziz; Simcha Weissman; Tej I Mehta; Shafae Hassan; Zubair Khan; Rawish Fatima; Yuriy Tsirlin; Ammar Hassan; Michael Sciarra; Ali Nawras; Amit Rastogi Journal: Ann Gastroenterol Date: 2020-01-20